|
Capecitabine Combined with Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Capecitabine Combined with Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Capecitabine Combined with Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Clinical research trials and Capecitabine Combined with Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Capecitabine Combined with Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors. Capecitabine Combined with Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Capecitabine Combined with Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors clinical trial. Subjects typically recieve the finest healthcare available for their Capecitabine Combined with Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Capecitabine Combined with Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors  Capecitabine Combined with Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Capecitabine Combined with Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
For Condition: unclassified and other cancer,thorax and respiratory cancer,Breast Cancer,Head and Neck Cancer,Gastrointestinal Cancer
Status: Recruiting
Sponsor(s): Kaplan Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of capecitabine combined with cisplatin in treating patients who have locally advanced or metastaticsolid tumors .
Details: OBJECTIVES: - Determine the dose-limiting toxicity, maximum tolerated dose, and the recommended phase II dose of capecitabine and cisplatin in patients with locally advanced or metastatic cancer of the upper gastrointestinal tract, head and neck, lung, breast, or carcinoma of unknown primary. - Determine the toxic effects of this regimen in these patients. - Evaluate possible antitumor effectiveness of this regimen in these patients. OUTLINE: This is a dose-escalation study of capecitabine. Patients receive oral capecitabine twice daily for 5, 10, or 14 days. Patients also receive cisplatin IV on day 1 of each course. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity (DLT). The recommended phase II dose is defined as the dose preceding the MTD, provided no more than 3 of 12 patients experience DLT at that dose. Patients are followed every 3 months for 6 months and then every 6 months thereafter. PROJECTED ACCRUAL: A total of 20-30 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed metastatic or locally advanced inoperable carcinoma of the upper gastrointestinal tract, head and neck, lung, breast, or carcinoma of unknown primary - Previously treated and/or resected primary tumors allowed - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age: - 18 and over Sex: - Not specified Menopausal status: - Not specified Performance status: - ECOG 0-2 Life expectancy: - At least 12 weeks Hematopoietic: - Absolute neutrophil count at least 1,500/mm3 - Platelet count at least 100,000/mm3 Hepatic: - Bilirubin less than 2 mg/dL* - AST less than 3 times upper limit of normal (ULN)* - Alkaline phosphatase no greater than 3 times ULN* NOTE: * Unless related to tumor (e.g., cholangiocarcinoma or hepatic metastases) Renal: - Creatinine no greater than 1.5 mg/dL OR - Creatinine clearance greater than 60 mL/min - BUN no greater than 30 mg/dL* NOTE: * Unless related to tumor (e.g., cholangiocarcinoma or hepatic metastases) Other: - No other medical condition that could interfere with oral medication absorption - No prior or concurrent malignancy except surgically cured carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - At least 6 months since prior fluorouracil or cisplatin - At least 3 weeks since other prior chemotherapy Endocrine therapy: - Not specified Radiotherapy: - At least 3 weeks since prior radiotherapy Surgery: - See Disease Characteristics
Total Enrollment:
Location and Contact Information:
Overall Study Official:
FrancoMuggia, Study Chair, Kaplan Cancer Center
NYU School of Medicine's Kaplan Comprehensive Cancer Center *Recruiting*
New York City, New York, 10016
United States
Recruiting Franco Muggia 212-263-6485
Additional Information:
Study ID Numbers: CDR0000068434; NCI-G00-1908,ROCHE-NYU-9955,NYU-9955
Study Start Date:
Record last reviewed: April 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00010023
Other Thorax And Respiratory Cancer Studies:
1. Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
2. PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer
3. Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer
4. Capecitabine Combined with Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Related Studies:
Other thorax and respiratory cancer Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Capecitabine Combined with Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
|
|
|
|
|
|
|
|
